XML 29 R18.htm IDEA: XBRL DOCUMENT
v3.25.3

GOODWILL AND INTANGIBLE ASSETS | 6 Months Ended
--- | ---
Sep. 27, 2025
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND INTANGIBLE ASSETS | 11. GOODWILL AND INTANGIBLE ASSETS The changes in the carrying amount of goodwill by operating segment for fiscal 2026 are as follows:
| Plasma |  | Blood Center |  | Hospital |  | Total
| (Dollars in Thousands)
Carrying amount as of March 29, 2025 | $ | 29,043 |  |  | $ | 26,967 |  |  | $ | 548,259 |  |  | $ | 604,269 |
Currency translation | — |  |  | 123 |  |  | 1,709 |  |  | 1,832 |
Carrying amount as of September 27, 2025 | $ | 29,043 |  |  | $ | 27,090 |  |  | $ | 549,968 |  |  | $ | 606,101 |
The gross carrying amount of intangible assets and the related accumulated amortization as of September 27, 2025 and March 29, 2025 are as follows:
| Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Weighted Average Remaining Life (Years)
September 27, 2025 | (Dollars in Thousands) |  |
Amortizable: |  |  |  |  |  |  |
Developed technology | $ | 509,111 |  |  | $ | 174,864 |  |  | $ | 334,247 |  |  | 12.1
Customer contracts and related relationships | 137,366 |  |  | 74,105 |  |  | 63,261 |  |  | 12.6
Capitalized software | 94,135 |  |  | 79,435 |  |  | 14,700 |  |  | 6.7
Patents and other | 7,468 |  |  | 4,348 |  |  | 3,120 |  |  | 10.0
Trade names | 16,082 |  |  | 6,841 |  |  | 9,241 |  |  | 12.3
Total | $ | 764,162 |  |  | $ | 339,593 |  |  | $ | 424,569 |  |  |
Non-amortizable: |  |  |  |  |  |  |
In-process software development | $ | 3,788 |  |  |  |  |  |  |
Total | $ | 3,788 |  |  |  |  |  |  |
| Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Weighted Average Remaining Life (Years)
March 29, 2025 | (Dollars in Thousands) |  |
Amortizable: |  |  |  |  |  |  |
Developed technology | $ | 506,143 |  |  | $ | 156,123 |  |  | $ | 350,020 |  |  | 12.1
Customer contracts and related relationships | 135,561 |  |  | 70,842 |  |  | 64,719 |  |  | 12.6
Capitalized software | 85,528 |  |  | 76,185 |  |  | 9,343 |  |  | 6.9
Patents and other | 19,678 |  |  | 6,796 |  |  | 12,882 |  |  | 8.5
Trade names | 15,955 |  |  | 6,367 |  |  | 9,588 |  |  | 12.3
Total | $ | 762,865 |  |  | $ | 316,313 |  |  | $ | 446,552 |  |  |
Non-amortizable: |  |  |  |  |  |  |
In-process software development | $ | 9,190 |  |  |  |  |  |  |
Total | $ | 9,190 |  |  |  |  |  |  |
In the second quarter of fiscal 2026, the Company recorded an intangible asset impairment charge of $8.6 million related to the intellectual property associated with the HAS viscoelastic diagnostic devices, related assays and disposables within the Hospital business unit, as acquired from HemoAssay Science and Technology (Suzhou) Co. Ltd., a China-incorporated company, and its affiliates (collectively, “HemoAssay”) in fiscal 2021. The impairment charge was the result of lower revenue projections of the HemoAssay devices and disposables. The fair value as September 27, 2025 was $1.6 million with a useful life of 5 years. We calculated the fair value of the HemoAssay intangible assets as the present value of estimated future cash flows we expect to generate from the assets based on estimates and assumptions about future revenues, costs and the remaining useful lives of the assets. During the second quarter of fiscal 2026, we performed an impairment analysis for certain other amortizable intangible assets based on undiscounted cash flows and concluded those assets were not impaired. We will continue to review intangible assets subject to amortization for impairment indicators in future periods in accordance with our normal review processes. Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationship s and trade names. During the three and six months ended September 27, 2025, amortization expense was $12.8 million and $26.1 million, respectively. During the three and six months ended September 28, 2024, amortization expense was $14.2 million and $28.7 million, respectively. Future annual amortization expense on intangible assets for the next five years is estimated to be as follows:
|  | Amortization Expense
|  | (Dollars in Thousands)
Remainder of Fiscal 2026 |  | $ | 24,914 |
Fiscal 2027 |  | $ | 48,158 |
Fiscal 2028 |  | $ | 46,382 |
Fiscal 2029 |  | $ | 45,135 |
Fiscal 2030 |  | $ | 43,873 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration